Skip to main content
Premium Trial:

Request an Annual Quote

DeCode's Q4 Revenues Rise 17 Percent as Loss Grows on Increased R&D Costs

NEW YORK (GenomeWeb News) — DeCode Genetics today said fourth-quarter revenues increased 17 percent as R&D spending rose 4 percent and lossed increased 10 percent.
 
Total receipts for the three months ended Dec. 31, 2006, rose to $11.5 million from $9.8 million year over year. DeCode said it has $9.8 million in deferred revenue which will be “recognized over future reporting periods.”
 
R&D spending increased to $14.2 million from $13.7 million year over year.
 
The company said losses increased to $23.2 million from $21.1 million in the year-ago period.
 
The increase in losses came from increased selling and other costs, and on increased R&D spending for clinical trials of the company’s arterial thrombosis and heart attack drugs, which are in Phase IIa and Phase I trials, respectively.
 
DeCode said it had around $152 million in cash and investments as of Dec. 31.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.